Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Reviewers: John Han-Chih Chang, MD and Kenneth Blank, MD
Source: New England Journal of Medicine, 339 (6):357
Bisphosphonates are a class of drugs that are increasingly being used totreat osteoporosis. These medications inhibit the function of the cellthat functions normally to destroy bone- the osteoclast. In 1996 a studypublished in the New England Journal of Medicine found that pamidronate-a bisphosphonate- reduced skeletal complications (fractures, bone painetc.) in women with breast cancer, and later that year the FDA approved pamidronate for use in this patient population, as well as in patientswith myeloma (a form of bone cancer).
A study published in the August 6, 1998 New England Journal of Medicinelooked at the effect of clodronate- a bisphosphonate- on the incidenceof metastasis in patients with breast cancer. The study limitedenrollment to patients who were shown to have cancer cells in their bonemarrow, and hence at high risk for developing bone metastasis. Thepatients were randomized to receive clodronate (1600mg per day, orallyfor two years) or nothing. Enrollment began in 1990 and closed 5 yearslater when 302 patients had agreed to participate. The median follow uptime was 36 months. Patients were treated for their breast cancer withstandard treatment including surgery, radiotherapy and chemotherapy.
The mean number of bone metastasis was significantly reduced in thegroup of patients receiving clodronate: 3.1 versus 6.1. In addition, thenumber of visceral metastasis (metastasis in body organs such as theliver and lung) was lower, and the number of patients who died was alsolower (6 versus 22).
The authors conclude that clodronate can reduce theincidence of new bony and visceral metastasis in high-risk breast cancerpatients. As with all studies, many questions remain willbisphosphonates prove effective in the majority of breast cancerpatients who do not have bone marrow involvement? And, are allbisphosphonates alike- or are some more effective than others? Finally,the follow-up was short- 3 years- and only with longer follow-up will itbe clear whether the clodronate actually prevents the formation if bonymetastasis or simply delays their appearance.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults